Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review

Sylvester N. Osayi; Mark Bloomston; Carl M. Schmidt; E. Christopher Ellison; Peter Muscarella

doi:10.1155/2014/468959

Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review

Sylvester N. Osayi, Mark Bloomston, Carl M. Schmidt, E. Christopher Ellison, Peter Muscarella

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

Original language	English (US)
Article number	468959
Journal	BioMed Research International
Volume	2014
DOIs	https://doi.org/10.1155/2014/468959
State	Published - 2014
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology
General Immunology and Microbiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2014/468959

Cite this

@article{0beda56f570b4a1c813bbc60833f7a8a,

title = "Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review",

abstract = "Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.",

author = "Osayi, {Sylvester N.} and Mark Bloomston and Schmidt, {Carl M.} and Ellison, {E. Christopher} and Peter Muscarella",

year = "2014",

doi = "10.1155/2014/468959",

language = "English (US)",

volume = "2014",

journal = "BioMed Research International",

issn = "2314-6133",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma

T2 - A review

AU - Osayi, Sylvester N.

AU - Bloomston, Mark

AU - Schmidt, Carl M.

AU - Ellison, E. Christopher

AU - Muscarella, Peter

PY - 2014

Y1 - 2014

N2 - Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

AB - Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

UR - http://www.scopus.com/inward/record.url?scp=84904159265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904159265&partnerID=8YFLogxK

U2 - 10.1155/2014/468959

DO - 10.1155/2014/468959

M3 - Review article

C2 - 25050350

AN - SCOPUS:84904159265

SN - 2314-6133

VL - 2014

JO - BioMed Research International

JF - BioMed Research International

M1 - 468959

ER -

Biomarkers as predictors of recurrence following curative resection for pancreatic ductal adenocarcinoma: A review

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this